Login or sign up
For business

BiPar Sciences

3.9· 10 reviews
Average ratingAverage
3.9/ 5

Based on 10 reviews

530%
430%
340%
20%
10%
Ask AI

Ask Trustburn about BiPar Sciences

Based on 10 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

Cheryl Schmidt
Reviews 1

I had a great experience with BiPar Sciences. Their website is user-friendly and easy to navigate. The information provided is clear and concise. The customer support team was also very helpful and responsive. Overall, I am very satisfied with the company's services.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About BiPar Sciences

BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar's key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors.

BiPar has raised around $60 million in VC funding, from firms like [Domain Associates](/financial-organization/domain-associates), [Canaan Partners](/financial-organization/canaan-partners-3), [Vulcan Capital](/financial-organization/vulcan-capital), [PolyTechnos Venture Partners](/financial-organization/polytechnos-venture-partners), [Asset Management Company](/financial-organization/asset-management), and [Quantum Technology Partners](/financial-organization/quantum-technology-partners). It also has raised venture debt from [Lighthouse Capital Partners](/financial-organization/lighthouse-capital-partners).

On April 15th, 2009, French drug maker [Sanofi-Aventis S.A.](/organization/sanofi-aventis-2) announced it was acquiring BiPar Sciences for up to $500 million.

Address
400 Oyster Point Blvd